Gosset Ownership
Private
Employees
~6
Therapeutic Areas
Stage
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Cessatech General Information
Cessatech’s lead product, CT001, is an analgesic nasal spray designed to treat acute pain in children. It leverages more than ten years of clinical experience with the active compound. The company uses a de-risked approach by repositioning existing medicines to fit pediatric needs, resulting in shorter development timelines and higher likelihood of regulatory success. Recent milestones include completion of pivotal studies and positive regulatory opinions under EU MDR
Contact Information
Drug Pipeline
CT001
Phase 3Key Partnerships
Proveca Ltd.: Exclusive commercial partnership worldwide excluding the US for CT001, Ventis Pharma Corporation – collaboration/license agreement on formulation/pain management therapies
Cessatech Funding
No funding data available
To view Cessatech's complete valuation and funding history, request access »